ClinicalTrials.gg

Program

ANXV

Its studies are mostly in Retinal Vein Occlusion, led by Annexin Pharmaceuticals AB.

Furthest: phase 2, since Jul 18, 20223 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Annexin Pharmaceuticals AB31 open or runningphase 2since Jul 18, 2022Mar 4, 2021none ahead

Also a collaborator on its studies: infocus-clinical-research.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 4, 2021First study: phase 1 study in HealthyFirst studyNCT04850339 · 46 enrolled · Netherlands
  2. Jul 18, 2022Phase 2 study in Retinal Vein OcclusionNCT05532735 · 16 enrolled · United States
  3. Sep 16, 2025Phase 2 study in Retinal Vein OcclusionNCT07259928 · 12 planned · United Kingdom

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07259928Retinal Vein Occlusion · United Kingdom2RecruitingJul 202612
NCT05532735Retinal Vein Occlusion · United States2CompletedJul 17, 202416
NCT04850339Healthy · Netherlands1CompletedOct 27, 202146

How it is read

Names in the registry

  • “ANXV”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.